| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56M | 846.19K | 403.53K | 132.77K | 11.34K | 0.00 |
| Gross Profit | 968.18K | 535.11K | 206.42K | 100.63K | 5.04K | -47.57K |
| EBITDA | -15.46M | -12.64M | -17.92M | -11.72M | -15.95M | -6.11M |
| Net Income | -16.29M | -13.39M | -18.94M | -3.59M | -16.76M | -8.00M |
Balance Sheet | ||||||
| Total Assets | 6.92M | 14.33M | 27.09M | 34.60M | 9.98M | 13.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.37M | 6.18M | 18.43M | 28.44M | 5.14M | 11.70M |
| Total Debt | 117.05K | 137.48K | 192.89K | 325.68K | 441.17K | 400.81K |
| Total Liabilities | 2.41M | 3.87M | 7.10M | 8.49M | 2.56M | 2.40M |
| Stockholders Equity | 4.51M | 10.45M | 15.06M | 26.11M | 7.42M | 10.76M |
Cash Flow | ||||||
| Free Cash Flow | -15.78M | -16.90M | -15.17M | -13.86M | -16.03M | -8.26M |
| Operating Cash Flow | -13.86M | -14.72M | -14.70M | -11.87M | -13.91M | -8.26M |
| Investing Cash Flow | -1.80M | -1.90M | 206.01K | -1.75M | -1.45M | 7.24M |
| Financing Cash Flow | 10.44M | 8.58M | 234.47K | 40.28M | 10.06M | 9.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | C$250.94M | ― | -106.37% | ― | 64.42% | -21.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$140.76M | -9.69 | -9.96% | ― | -0.70% | -102.48% | |
48 Neutral | C$23.42M | ― | -26.27% | ― | 17.61% | -19.19% | |
46 Neutral | C$29.10M | -0.90 | -233.44% | ― | 219.12% | -15.92% | |
45 Neutral | C$53.98M | -12.00 | -291.69% | ― | 16.00% | 9.79% | |
44 Neutral | C$15.93M | ― | ― | ― | 88.47% | 11.88% |
Perimeter Medical Imaging AI announced its participation in the American Society of Breast Surgeons’ Annual Strategic Futures Forum, a key event for healthcare leaders to discuss the future of breast surgery. This involvement allows Perimeter to engage with leaders in the breast surgeon community, potentially influencing their product development and enhancing breast care solutions. The forum’s theme emphasizes the importance of multi-disciplinary collaboration in improving breast care outcomes.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced its participation in the Planet MicroCap Showcase in Toronto, where CEO Adrian Mendes will present updates on the company’s commercial strategy and upcoming milestones. This event, which gathers investors and analysts, provides Perimeter with an opportunity to enhance its industry positioning and engage with potential stakeholders, highlighting its focus on advanced imaging tools for cancer surgery.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced that its CEO, Adrian Mendes, will present an update on the company’s business at the Small Cap Growth Virtual Investor Conference. This presentation is significant as it targets a global audience of small-cap retail and institutional investors, potentially impacting the company’s visibility and investor relations. The company’s focus on advanced imaging tools for cancer surgery positions it strategically within the medical technology industry, with ongoing evaluations and developments that could influence its market presence.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced its participation in the Aptitude Health/TME’s Fall Summit on Breast Cancer Care, showcasing its innovative optical coherence tomography (OCT) technology. This event is a significant opportunity for Perimeter to present its technology to leading breast cancer physicians, potentially advancing intraoperative care and enhancing its market position in the medical imaging industry.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI announced that Dr. Amelia Tower will present at the American College of Osteopathic Surgeons’ Annual Clinical Assembly on the use of wide-field optical coherence tomography (OCT) in breast conserving surgery. The presentation will highlight the practical application of Perimeter’s S-Series OCT, which has FDA clearance, and its potential to reduce re-excision rates by providing real-time insights during surgery. This event underscores the growing clinical evidence supporting the integration of advanced imaging technologies in surgical workflows, potentially enhancing precision and decision-making in breast cancer surgeries.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI has announced a collaboration with Jennifer Douglas, a breast cancer survivor and advocate, to enhance patient engagement initiatives. Douglas will join the company’s Industry Advisory Board, contributing her experience to support breast cancer patients and improve outcomes. This partnership is expected to strengthen Perimeter’s focus on patient support and expand its influence in the breast cancer community.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI has joined the American Society of Breast Surgeons’ Industry Relations Council, a move that aligns with its strategic goals to enhance its presence in the breast surgery field. This membership is expected to facilitate collaboration with key industry leaders and support the company’s efforts to gain commercial traction for its current and next-generation imaging systems, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI Inc. recently held its earnings call, revealing a mix of promising developments and ongoing challenges. The sentiment was largely positive, highlighted by strong revenue growth, successful clinical trials, and increased product utilization. However, the company faces hurdles such as rising net losses, limited cash reserves, and constraints from a small commercial team. These factors underscore the need for strategic adjustments moving forward.
Perimeter Medical Imaging AI has appointed Dr. Ted James as Chief Medical Officer to bolster its medical strategy and accelerate the adoption of its technology. Dr. James, with extensive experience in surgical oncology and healthcare innovation, will support the company’s growth as it moves towards commercialization of its next-generation AI-enabled imaging tools. His appointment is expected to enhance the company’s industry positioning by demonstrating the medical and practical value of its Perimeter B-Series technology, which is advancing toward FDA approval.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI reported a significant increase in revenue for the second quarter of 2025, driven by the growing adoption of its FDA-cleared Perimeter S-Series device. The company also highlighted the promising development of its next-generation Perimeter B-Series device, which integrates AI technology to improve surgical decision-making. Recent partnerships and the launch of a new registry aim to support further advancements in their imaging technology. The company’s financial health was bolstered by a successful prospectus offering, raising approximately $3.8 million to support ongoing operations and development efforts.
The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.
Perimeter Medical Imaging AI, Inc. announced preliminary unaudited revenues for the second quarter of 2025, showing significant growth with a 100% year-over-year increase and a 50% rise in recurring revenue compared to the previous quarter. The company is implementing a 30% reduction in operating costs and has made strategic leadership changes to support its growth, including the appointment of new vice presidents and the creation of an Industry Advisory Board to guide its commercial strategy.
The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.